Brief Summary
This is an open-label, dose-escalation, multi-center phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of SR-8541A, an ENPP1 inhibitor, administered orally as a monotherapy in subjects with solid tumors.
Intervention / Treatment
- Drug: SR-8541A
Inclusion Criteria:
- Life expectancy of at least 3 months
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status 0 – 1
- Histopathologically/cytologically confirmed advancedat a late stage, far along solid tumor, which is refractory to standard therapeutic options, or for which there are no standard therapeutic options.
- Measurable disease per RECIST v1.1
- Willing to provide archival or fresh tumor tissuea group of cells that work together to perform a function during screeningtesting for cancer or conditions that can lead to cancer before symptoms appear, also known as cancer screening (required) and post-treatment (optional)
- Adequate hematologic, renal and hepatic function.